ClinicalTrials.gg
CompletedNCT06760182Updated Aug 12, 2025

Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic Rhinitis

A Phase 2 interventional study of TQH2722 injection and TQH2722 Placebo in Seasonal Allergic Rhinitis, sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.. Completed at 30 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
169
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Rhinitis, Allergic, Seasonal with a site in China — 12 open to participants now, 14 under way, 8 of them phase 3. Rhinitis, Allergic, Seasonal · China.

Enrollment
13th of 27
169 · median 160
Started
2025
with 8 others
Phase 2
12 of 27
5 open now
Registered
12th of 27
by date
Lead sponsor
2 of 27
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Among the 27 studies in Rhinitis, Allergic, Seasonal with a site in China, this one is the 13th largest by enrollment, is one of 9 that started in 2025, is one of 12 in phase 2, and was the 12th registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

12 of the 27 studies in Rhinitis, Allergic, Seasonal with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Rhinitis, Allergic, Seasonal with a site in China, or all of them as a file.
02

Study summary

To evaluate TQH2722 injection in all patients receiving background treatment with mometasone furoate nasal spray (MFNS) and loratadine. The efficacy, safety and immunogenicity of the solution in patients with seasonal allergic rhinitis compared with placebo are expected to include 168 patients with confirmed seasonal allergic rhinitis (SAR) who have failed to respond to standard treatments.

03

Conditions studied

  • Seasonal Allergic Rhinitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 75 years at the screening period.
  • Patients who met the diagnostic criteria of allergic rhinitis in Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (revised edition, 2022)
  • Positive of at least 1 allergen skin prick test(SPT) and/or serum-specific IgE within 1 year before enrollment.
  • Subjects have sufficient pollen exposure during the pollen season:
  • Subjects' medical history suggested that SAR symptoms were poorly controlled or subjects' subjective symptoms were not satisfactorily controlled after drug treatment during the same pollen season in the past.
  • On the day of screening, the iTNSS score in the morning was ≥4; At baseline visit, the morning iTNSS was ≥4 points, and the average score of the past 6 rTNSS was ≥6 points;
  • At baseline visit, the absolute value of peripheral blood eosinophils was ≥0.15×109/L;
  • During the screening/induction period, the subjects had good compliance;
  • Subjects with asthma who were assessed by the investigator or specialist as having stable asthma;
  • Voluntary participation in this trial and signing the form
  • Subjects (including partners) have no pregnancy and voluntarily take one or more non-pharmaceutical measures for at period from drug administration to 6 months after the last study drug administration

Exclusion criteria

Exclusion Criteria:

  • Laboratory test values did not meet the requirements during screening or randomization
  • Any disease that the investigator believes interferes with the patient's ability to complete the entire course of the study;
  • Patients with active disease
  • People with known or suspected
  • Subjects with active or a history of malignancy;
  • Active hepatitis or was present during the screening period; Or antibody (Anti-HIV) positive, or treponema pallidum antibody (Anti-TP) positive;
  • Diagnosis of helminthic infection within 6 months prior to screening, not receiving standard treatment or not responding to standard treatment;
  • Subjects who have undergone nasal surgery or sinus surgery within 6 months before screening
  • Subjects have concomitant medical conditions that preclude them from completing the screening period assessment or evaluating the primary efficacy endpoint;
  • Subjects with nasal malignancies and benign tumors;
  • History of to any content of the study drugs or its
  • Subjects with a history of systemic allergy to any biological agent;
  • Pregnant or lactating women;
  • Alcohol, drug and known drug dependence;
  • Have a history of vital organ transplantation or hematopoietic stem cell/bone marrow transplantation;
  • Any medical or psychiatric condition that, in the investigator's judgment, puts the subject at risk, interferes with participation in the study, or interferes with the interpretation of the study results;
  • Any condition that the investigator or primary physician believes may not be appropriate for participating the study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
169 participants (actual)

Study arms

  • Experimental
    TQH2722 injection

    Drug: TQH2722 injection

  • Placebo comparator
    TQH2722 Placebo

    TQH2722 placebo, 1 weeks as a treatment cycle.

    Drug: TQH2722 Placebo

Interventions

  • TQH2722 injection is a humanized monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα).

  • DrugTQH2722 Placebo

    Placebo without drug substance.

06

What researchers measure

Primary outcomes

  1. Retrospective nasal symptom score after treatment for 2 weeks

    Average daily retrospective nasal symptom score (rTNSS) changed from baseline after 2 weeks of treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 weeks

Secondary outcomes

  1. Retrospective nasal symptom score after treatment for 4 weeks

    Mean daily retrospective nasal symptom total score (rTNSS) changes from baseline at 4 weeks of treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 4 weeks

  2. Mean daily changes in retrospective nasal symptom total score

    Mean daily changes in retrospective nasal symptom total score (AM rTNSS) from baseline at 2 weeks and 4 weeks after treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  3. Mean daily nightly retrospective nasal symptom total score

    Mean daily nightly retrospective nasal symptom total score (PM rTNSS) changes from baseline at 2 weeks and 4 weeks after treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  4. Instantaneous nasal symptom score: Mean change of instantaneous nasal symptom total score (iTNSS) from baseline

    Mean change of instantaneous nasal symptom total score (iTNSS) from baseline every morning before treatment for 2 weeks and 4 weeks. The total score is 0-12 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  5. Instantaneous nasal symptom score: Mean daily rTNSS change from baseline

    Mean daily rTNSSchange from baseline at 2 weeks and 4 weeks of treatment; The total score is 0-12 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  6. Instantaneous nasal symptom score: Mean change rate of iTNSS from baseline

    Mean change rate of iTNSS from baseline before treatment at 2 weeks and 4 weeks each morning. The total score is 0-12 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  7. Instantaneous nasal single symptom score: Mean changes from baseline in daily retrospective nasal symptom scores

    Mean changes from baseline in daily retrospective nasal symptom scores (runny nose, nasal congestion, nasal itchy, and sneezing) at 2 and 4 weeks of treatment. The single score is 0-3 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  8. Instantaneous nasal single symptom score: Mean changes from baseline in scores of individual nasal symptoms during the day

    Mean changes from baseline in scores of individual nasal symptoms (runny nose, nasal congestion, itchy nose, and sneezing) were reviewed daily (AM) at 2 weeks and 4 weeks of treatment. The single score is 0-3 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  9. Instantaneous nasal single symptom score: Mean changes from baseline in scores of individual nasal symptoms at night

    Mean changes from baseline in scores of individual nasal symptoms (runny nose, nasal congestion, nasal itchy and sneezing) at night (PM) after 2 and 4 weeks of treatment. The single score is 0-3 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  10. Retrospective ocular symptom score: Mean changes in daily retrospective ocular symptom score

    Mean changes in daily retrospective ocular symptom score (rTOSS) from baseline at 2 and 4 weeks of treatment; The total score is 0-9 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  11. Retrospective ocular symptom score: Mean changes in retrospective ocular symptom score during the day

    Mean daily changes in retrospective ocular symptom score (AM rTOSS) from baseline at 2 weeks and 4 weeks of treatment. The total score is 0-9 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  12. Retrospective ocular symptom score: Mean retrospective ocular symptom score at night

    Mean nightly retrospective ocular symptom score (PM rTOSS) changes from baseline at 2 weeks and 4 weeks of treatment. The total score is 0-9 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  13. Retrospective ocular symptom score: Mean change of instantaneous ocular symptom total score

    Mean change of instantaneous ocular symptom total score (iTOSS) from baseline every morning at 2 weeks and 4 weeks of treatment. The total score is 0-9 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  14. Retrospective ocular symptom score: Mean rate of change in daily rTOSS

    Mean rate of change in daily rTOSS from baseline at 2 and 4 weeks of treatment. The total score is 0-9 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  15. Retrospective nasal symptom score: Average daily retrospective nasal symptom score

    Average daily retrospective nasal symptom score (rTNSS) changed from baseline after 4 weeks of treatment. The total score is 0-12points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 4 weeks

  16. Retrospective ocular symptom score: Mean change rate of iTOSS each morning

    Mean change rate of iTOSS from baseline before treatment at 2 weeks and 4 weeks each morning. The total score is 0-9 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  17. Instantaneous ocular single symptom score: Average changes in scores of individual ocular symptoms

    Average changes in scores of individual ocular symptoms (itchy, tearing, red eyes) at 2 and 4 weeks of treatment compared with baseline. The single score is 0-3 points, with the higher score meaning the more severe symptoms

    Time frame: Baseline up to 2 and 4 weeks

  18. Instantaneous ocular single symptom score: Average changes of individual ocular symptom scores during the day

    Average changes of individual ocular symptom scores (itchy, watery eyes, red eyes) compared with baseline were reviewed daily (AM) at 2 weeks and 4 weeks of treatment. The single score is 0-3 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  19. Instantaneous ocular single symptom score: Average changes of individual ocular symptoms at night

    Average changes of individual ocular symptoms (itchy, watery eyes, red eyes) scores at night (PM) after 2 weeks of treatment and 4 weeks of treatment compared with baseline. The single score is 0-3 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  20. Quality of life questionnaire

    Changes in quality of life questionnaire (RQLQ) scores from baseline for patients with allergic rhinitis after 2 weeks and 4 weeks of treatment. The total score is 0-168 points, with the higher score meaning the more severe symptoms.

    Time frame: Baseline up to 2 and 4 weeks

  21. Time of onset

    Time of onset after treatment.

    Time frame: Baseline up to 4 weeks

  22. Time to Reach Maximum Plasma Concentration (Tmax)

    Time to reach maximum plasma concentration after administration.

    Time frame: Baseline up to 4 weeks

  23. Area under the curve

    Area under the curve of mean daily rTNSS change from baseline at 2 and 4 weeks of treatment

    Time frame: Baseline up to 2 and 4 weeks

  24. Number of days with no or mild symptoms of Allergic rhinitis symptoms

    Number of days with no or mild symptoms during 2 weeks and 4 weeks of treatment

    Time frame: Baseline up to 2 and 4 weeks

  25. Adverse event rate

    Incidence and severity of adverse events (AE) and serious adverse events (SAE), physical examination, vital signs, 12-lead electrocardiogram (ECG), and abnormal laboratory indicators.

    Time frame: Baseline up to 12 weeks

07

Study locations

30 sites
  • Peking University First Hospital
    Beijing, Beijing Municipality 100034, China
  • Peking University People's Hospital
    Beijing, Beijing Municipality 100044, China
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100191, China
  • Gansu Provincial Hospital
    Lanzhou, Gansu 730000, China
  • Cangzhou Central Hospital
    Cangzhou, Hebei 061017, China
  • Hebei Medical University Third Hospital
    Shijiazhuang, Hebei 50000, China
  • Henan Provincial People's Hospital
    Zhengzhou, Henan 450000, China
  • The Central Hospital of Wuhan
    Wuhan, Hubei 430014, China
  • Union Hospital, Tongji Medical College, Huazhong University of science and technology
    Wuhan, Hubei 430022, China
  • Tongji Hospital of Tongji medical college of HUST
    Wuhan, Hubei 430030, China
  • Zhongnan Hospital of Wuhan University
    Wuhan, Hubei 430071, China
  • Baotou Central Hospital
    Baotou, Inner Mongolia 014000, China
  • Chifeng Municipal Hospital
    Chifeng, Inner Mongolia 024005, China
  • The Affiliated Hospital of Inner Mongolia Medical University
    Hohhot, Inner Mongolia 015000, China
  • Ansteel Group General hospital
    Anshan, Liaoning 114000, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning 110004, China
  • Liaoning Health Industry Group Iron Coal General Hospital
    Tieling, Liaoning 112700, China
  • The First People's Hospital of Yinchuan
    Yinchuan, Ningxia 750000, China
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710004, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710061, China
  • Shandong Second Provincial General Hospital
    Jinan, Shandong 250000, China
  • Qilu Hospital of Shandong University
    Qilu, Shandong 250012, China
  • Yantai Yuhuangding Hospital
    Yantai, Shandong 264000, China
  • Zibo Central Hospital
    Zibo, Shandong 255036, China
  • Shanxi Bethune Hospital
    Taiyuan, Shanxi 030000, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin Municipality 300041, China
  • Tianjin People's Hospital
    Tianjin, Tianjin Municipality 300121, China
  • Tianjin First Central Hospital
    Tianjin, Tianjin Municipality 300192, China
  • The First Affiliated Hospital of Xinjiang Medical University
    Ürümqi, Xinjiang 830054, China
  • The First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650032, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Apr 2025, 1 month.

Of 24 phase 2 interventional studies under Rhinitis, Allergic, Seasonal, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 23. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2024
First posted
Jan 6, 2025
StartActual
Mar 10, 2025
Primary completionActual
Apr 30, 2025
CompletionActual
Jul 1, 2025
Last update
Aug 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06760182
Responsible party
Sponsor
First posted
Jan 6, 2025
Start date
Mar 10, 2025
Primary completion
Apr 30, 2025
Completion
Jul 1, 2025
Last update
Aug 12, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQH2722

Start the discussion